OBJECTIVE: This study provides detailed information about stimulant medication treatment for the target symptoms of hyperactivity, impulsivity, disinhibition, and inattention in children with autism. METHODS: In a previous study, 124 subjects fulfilling DSM-IV-based research criteria for autistic disorder were identified among all 0-21 year old residents of Olmsted County, MN from 1976-1997. For each of these 124 children with research-identified autism, information was abstracted on all prescribed psychopharmacological medications. RESULTS: Psychostimulants were used to treat 52.4% (N = 65) of the 124 subjects. The median total duration of psychostimulant treatment was 4.0 years. There were 398 episodes of psychostimulant treatment. Favorable responses were associated with 69.4% of treatment episodes. Of the 398 episodes of stimulant treatment, 16.8% were associated with a documented side effect. At least one side effect was experienced by 66% of the children. CONCLUSION: These results indicate that psychostimulants are commonly prescribed for children with autism, and suggest that these medications may improve the target symptoms of hyperactivity, impulsivity, disinhibition and inattention.
OBJECTIVE: This study provides detailed information about stimulant medication treatment for the target symptoms of hyperactivity, impulsivity, disinhibition, and inattention in children with autism. METHODS: In a previous study, 124 subjects fulfilling DSM-IV-based research criteria for autistic disorder were identified among all 0-21 year old residents of Olmsted County, MN from 1976-1997. For each of these 124 children with research-identified autism, information was abstracted on all prescribed psychopharmacological medications. RESULTS: Psychostimulants were used to treat 52.4% (N = 65) of the 124 subjects. The median total duration of psychostimulant treatment was 4.0 years. There were 398 episodes of psychostimulant treatment. Favorable responses were associated with 69.4% of treatment episodes. Of the 398 episodes of stimulant treatment, 16.8% were associated with a documented side effect. At least one side effect was experienced by 66% of the children. CONCLUSION: These results indicate that psychostimulants are commonly prescribed for children with autism, and suggest that these medications may improve the target symptoms of hyperactivity, impulsivity, disinhibition and inattention.
Authors: L L Greenhill; J M Swanson; B Vitiello; M Davies; W Clevenger; M Wu; L E Arnold; H B Abikoff; O G Bukstein; C K Conners; G R Elliott; L Hechtman; S P Hinshaw; B Hoza; P S Jensen; H C Kraemer; J S March; J H Newcorn; J B Severe; K Wells; T Wigal Journal: J Am Acad Child Adolesc Psychiatry Date: 2001-02 Impact factor: 8.829
Authors: Deborah A Pearson; Cynthia W Santos; John D Roache; Charles D Casat; Katherine A Loveland; David Lachar; David M Lane; Laura P Faria; Lynne A Cleveland Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-02 Impact factor: 8.829
Authors: Thomas W Frazier; Paul T Shattuck; Sarah Carter Narendorf; Benjamin P Cooper; Mary Wagner; Edward L Spitznagel Journal: J Child Adolesc Psychopharmacol Date: 2011-12-13 Impact factor: 2.576
Authors: Deborah A Pearson; Cynthia W Santos; Michael G Aman; L Eugene Arnold; David M Lane; Katherine A Loveland; Rosleen Mansour; Anthony R Ward; Charles D Casat; Susan Jerger; Russell J Schachar; Oscar G Bukstein; Lynne A Cleveland Journal: J Child Adolesc Psychopharmacol Date: 2020-07-09 Impact factor: 2.576
Authors: Tracy A Becerra; Maria L Massolo; Vincent M Yau; Ashli A Owen-Smith; Frances L Lynch; Phillip M Crawford; Kathryn A Pearson; Magdalena E Pomichowski; Virginia P Quinn; Cathleen K Yoshida; Lisa A Croen Journal: Perm J Date: 2017
Authors: Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson Journal: BMC Psychiatry Date: 2010-09-03 Impact factor: 3.630
Authors: Jill L Silverman; Brooke A Babineau; Chicora F Oliver; Michael N Karras; Jacqueline N Crawley Journal: Neuropharmacology Date: 2012-08-08 Impact factor: 5.250
Authors: Samar H Ibrahim; Robert G Voigt; Slavica K Katusic; Amy L Weaver; William J Barbaresi Journal: Pediatrics Date: 2009-07-27 Impact factor: 7.124
Authors: Deborah A Pearson; Cynthia W Santos; Michael G Aman; L Eugene Arnold; Charles D Casat; Rosleen Mansour; David M Lane; Katherine A Loveland; Oscar G Bukstein; Susan W Jerger; Perry Factor; Salome Vanwoerden; Evelyn Perez; Lynne A Cleveland Journal: J Child Adolesc Psychopharmacol Date: 2013-06 Impact factor: 2.576
Authors: E S Onaivi; R Benno; T Halpern; M Mehanovic; N Schanz; C Sanders; X Yan; H Ishiguro; Q-R Liu; A L Berzal; M P Viveros; S F Ali Journal: Curr Neuropharmacol Date: 2011-03 Impact factor: 7.363